StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Free Report) in a research note released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Stock Performance
Shares of AGRX opened at $1.46 on Friday. The stock has a fifty day moving average of $1.09 and a two-hundred day moving average of $0.81. The company has a market capitalization of $10.01 million, a PE ratio of -0.40 and a beta of 1.58. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.63.
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter. The business had revenue of $5.72 million during the quarter.
Institutional Inflows and Outflows
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Further Reading
- Five stocks we like better than Agile Therapeutics
- Investing In Automotive Stocks
- How to Invest in Silver: A Beginner’s Guide
- Stock Dividend Cuts Happen Are You Ready?
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Financial Services Stocks Investing
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.